JiaLi C. Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
JiaLi C. Huang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Angela L. Ferguson
School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
1 shared publication - Badwi B. Boumelhem
Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication - Geoffrey William McCaughan
Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication - Jasmine Minh Hang Nguyen
Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication - Katharine A. Osborne
NSW Health Pathology, Lidcombe, NSW 2141, Australia
1 shared publication - Ken Liu
AW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital Sydney Australia
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 44837
Understanding the Cancer-Associated Fibroblast (CAF) and Its Biomarker Fibroblast Activation Protein (FAP), and Aspects in Human Liver Cancer
Tumours contain many fibroblasts, endothelial cells, and leukocytes that are emerging as therapeutic targets complementary to targeting genetically unstable cancer cells. Immunotherapies directed towards this tumour microenvironment (TME) are increasingly effective. Targeting the endothelium has shown success, particularly in hepatocellular carcinoma (HCC). Cancer-associated fibroblasts (CAFs) are also attracting novel nascent therapeutic approaches, and fibroblast activation protein (FAP), which is specific to activated mesenchyme, is prominent amongst CAF markers. This review places emphasis upon FAP, human HCC, and FAP-targeting approaches for therapeutic benefit, including FAP inhibitors, radioligand therapy, T cell and antibody-dependent cytotoxicity/immunotherapy, and FAP-activated prodrugs.
- 22 December 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (12) , 44837
Open AccessUnderstanding the Cancer-Associated Fibroblast (CAF) and Its Biomarker Fibroblast Activation Protein (FAP), and Aspects in Human Liver Cancer
Tumours contain many fibroblasts, endothelial cells, and leukocytes that are emerging as therapeutic targets complementary to targeting genetically unstable cancer cells. Immunotherapies directed towards this tumour microenvironment (TME) are increasingly effective. Targeting the endothelium has shown success, particularly in hepatocellular carcinoma (HCC). Cancer-associated fibroblasts (CAFs) are also attracting novel nascent therapeutic approaches, and fibroblast activation protein (FAP), which is specific to activated mesenchyme, is prominent amongst CAF markers. This review places emphasis upon FAP, human HCC, and FAP-targeting approaches for therapeutic benefit, including FAP inhibitors, radioligand therapy, T cell and antibody-dependent cytotoxicity/immunotherapy, and FAP-activated prodrugs.